Iovance Biotherapeutics, Inc. (IOVA) Cash Flow Statement

The positive OCF/NI ratio in 2026Q2 is misleading because it stems from a large working capital drain, likely reflecting inventory build-up for commercial manufacturing. Over the past year, OCF/NI has fluctuated between 0.60 and 1.29, indicating that cash burn is not consistently aligned with reported losses. Investors should monitor whether working capital swings stabilize as the launch matures, as the underlying cash burn remains substantial.

The FCF trajectory shows a modest improvement from the -$126.5M in 2024Q1, but the absolute burn remains high, and FCF margins have swung wildly from -176.9% to -2.2% due to revenue timing and cost fluctuations. The gap between net income and FCF is widening, suggesting that capital expenditures and working capital needs are outpacing the revenue ramp. This implies that the company will require continued external funding to sustain operations.

The rise in capital intensity aligns with the company's vertical integration strategy, as it expands its manufacturing footprint to support Amtagvi's launch. However, the absolute CapEx is small relative to the company's cash burn, suggesting that the major capital outlays may have already occurred or are being deferred. Investors should watch for potential increases in CapEx as the company scales production to meet demand.

The working capital volatility is a key driver of the cash flow variability, with outflows in most quarters but a positive $9.2M in 2025Q2. This pattern suggests that the company is investing heavily in inventory and other current assets to support the therapy's distribution, which may be a temporary phenomenon as the supply chain stabilizes. However, the persistent outflows indicate that the company's cash conversion cycle is lengthening, which could strain liquidity if not managed.

The absence of capital returns is typical for a commercial-stage biotech, but the reliance on equity funding raises dilution concerns. The company's cash burn, averaging around $80M per quarter, suggests that it will need to access capital markets periodically, which could pressure the stock. The acquisition of Proleukin in 2024Q1 for $52.6M was a strategic use of cash, but the ongoing operational losses mean that external financing is inevitable.

The cumulative gap between net income and operating cash flow is positive, meaning that operating cash flow is less negative than net income, which is unusual for a loss-making company. This is likely due to significant non-cash expenses, including stock-based compensation and depreciation, which totaled over $200M in the period. However, the absolute cash burn remains substantial, and the company's ability to narrow this gap will depend on achieving operating leverage as revenue scales.